VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Fortinet, Inc. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Fortinet, Inc.
FTNT · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Fortinet, Inc.'s moat claims, evidence, and risks.
View FTNT analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Fortinet, Inc. leads (84 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Fortinet, Inc. has 2 segments (68% in Subscriptions & Support Services); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Fortinet, Inc. has 7 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Fortinet, Inc.
Subscriptions & Support Services
Cybersecurity subscriptions and technical support for Fortinet installed base (FortiGuard + FortiCare)
Global
Installed-base enterprises and channel partners
Vendor (subscription/support services)
68%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Fortinet, Inc. strengths
Gilead Sciences, Inc. strengths
Segment mix
Fortinet, Inc. segments
Full profile >Secure Networking Products
Oligopoly
Subscriptions & Support Services
Quasi-Monopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.